UBS Group’s Petros Pharmaceuticals PTPI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,763
| Closed | -$8.22K | – | 10728 |
|
|
2025
Q1 | $8.22K | Buy |
4,763
+4,243
| +816% | +$21.7K | ﹤0.01% | 8769 |
|
|
2024
Q4 | $5.12K | Sell |
520
-1,249
| -71% | -$10.2K | ﹤0.01% | 8697 |
|
|
2024
Q3 | $15.8K | Buy |
+1,769
| New | +$16.6K | ﹤0.01% | 7500 |
|
|
2023
Q1 | – | Sell |
-44
| Closed | -$2.56K | – | 10214 |
|
|
2022
Q4 | $2.56K | Buy |
+44
| New | +$4.25K | ﹤0.01% | 9658 |
|
|
2022
Q2 | – | Sell |
-19
| Closed | -$8K | – | 10794 |
|
|
2022
Q1 | $8K | Buy |
19
+11
| +138% | +$4.64K | ﹤0.01% | 8694 |
|
|
2021
Q4 | $7K | Sell |
8
-6
| -43% | -$3.52K | ﹤0.01% | 9162 |
|
|
2021
Q3 | $7K | Buy |
14
+10
| +250% | +$6.5K | ﹤0.01% | 8323 |
|
|
2021
Q2 | $3K | Buy |
+4
| New | +$3.2K | ﹤0.01% | 8835 |
|
|
2021
Q1 | – | Sell |
-11
| Closed | -$13K | – | 9371 |
|
|
2020
Q4 | $13K | Buy |
+11
| New | +$10.3K | ﹤0.01% | 7285 |
|
UBS Group's PTPI Position: Q2 2025 in Review
UBS Group sold out of Petros Pharmaceuticals (PTPI) in Q2 2025, closing a stake of 4,763 shares — an estimated $8.22K sold.
UBS Group first reported a position in PTPI in Q4 2020 and held it in 9 quarters. The position peaked at $15.8K in Q3 2024. 0 funds tracked by Wall St. Rank hold PTPI as of Q2 2025.
- UBS Group reported no remaining Petros Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- UBS Group sold 4,763 Petros Pharmaceuticals shares in Q2 2025, an estimated $8.22K.
- UBS Group first reported a position in Petros Pharmaceuticals in Q4 2020 and held it in 9 quarters.
- UBS Group's Petros Pharmaceuticals position peaked at $15.8K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2025.
Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.